

1 **Appendix:**

2 **Longitudinal SARS-CoV-2 seroprevalence in a rural and urban community household cohort in**
3 **South Africa, during the first and second waves July 2020-March 2021**

4 Jackie Kleynhans* (MPH), Stefano Tempia (PhD), Nicole Wolter (PhD), Anne von Gottberg (PhD), Jinal
5 N. Bhiman (PhD), Amelia Buys (MTech), Jocelyn Moyes (MD), Meredith McMorrow (MD), Kathleen
6 Kahn (PhD), Xavier Gómez-Olivé (PhD), Stephen Tollman (PhD), Neil Martinson (MD), Floidy
7 Wafawanaka (MSc), Limakatso Lebina (MD), Jacques du Toit (MD), Waasila Jassat (MD), Mzimasi
8 Neti (MPH), Marieke Brauer (MMed Path), Cheryl Cohen (PhD), for the PHIRST-C Group.

9 *corresponding author: jackiel@nicd.ac.za

10

11 **Table of contents**

Methods	2
Appendix tables	5
Appendix Table 1. Comparison of characteristics between district (Ehlanzeni and Dr Kenneth Kaunda Districts) and PHIRST-C cohort population, 2020, South Africa	5
Appendix Table 2. Number of sera collected (n) from consenting PHIRST-C participants (N) and percentage sampled during blood draws (BD) in the rural and urban community by blood draw, site, age group, March 2020 – March 2021, South Africa	5
Appendix Table 3. Individuals seropositive for SARS-CoV-2 antibodies with adjusted seroprevalence and 95% creditable intervals by blood draw, site and age, July 2020 – April 2021, South Africa	6
Appendix Table 4. SARS-CoV-2 seroprevalence from the fifth blood collection (22 March – 11 April 2021), by site, age group and HIV status, South Africa	6
Appendix figures	7
Appendix Figure 1. Location of study sites PHIRST-C, South Africa	7
Appendix Figure 2. WHO population age-standardised SARS-CoV-2 infection, diagnosis, hospitalisation and deaths per 100,000 population in a rural community during a) wave 1 and b) wave 2, and urban community during c) wave 1 and d) wave 2 of infections, South Africa, March 2020 - March 2021	8
The PHIRST-C Group	9
References	11

12

13 **Methods**

14 *Study population*

15 PHIRST-C (A Prospective Household study of SARS-CoV-2, Influenza, and Respiratory Syncytial virus
16 community burden, Transmission dynamics and viral interaction in South Africa) is a continuation
17 from PHIRST (A Prospective Household observational cohort study of Influenza, Respiratory Syncytial
18 virus and other respiratory pathogens community burden and Transmission dynamics in South
19 Africa).¹ PHIRST-C is conducted in two communities with established influenza-like illness and
20 pneumonia surveillance sites (Appendix figure 1).

21 South Africa consists of nine provinces, which are divided into 52 districts, which form the second
22 level of administration. Districts are further divided into municipalities. The rural site is located in the
23 Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province and forms part of a health and
24 socio-demographic surveillance site (HDSS) at the Medical Research Council (MRC)/University of
25 Witwatersrand Rural Public Health and Health Transitions Research Unit, Agincourt. During PHIRST,
26 two of the 29 villages within the HDSS were selected according to convenience (proximity and
27 burden of other studies within the site) each year between 2016-2018. A random selection of ~50
28 households with a household size of 3 or more were approached for enrolment. The urban site is
29 located in the Jouberton Township, Matlosana Municipality, Dr Kenneth Kaunda District, North West
30 Province. A list of 450 global positioning system (GPS) coordinates were generated using Google
31 Earth. Study staff approached the nearest house within 30 meters of the coordinate point for
32 enrolment. Approximately 50 households were enrolled each year from 2016-2018. At both sites,
33 households were eligible if they consisted of three or more household members (sharing at least
34 four meals a week). All household members were approached for inclusion in the study, and
35 households were eligible for inclusion if >80% of members consented to be enrolled.

36 For PHIRST-C, all households who participated in PHIRST from the urban site, and households from
37 the 2017 and 2018 cohort in the rural site were approached for enrolment. To appendix the sample

38 size, additional households at each site were approached using the same methods as for PHIRST.
39 Villages in the rural site were restricted to those four used in 2017 and 2018 of PHIRST. Informed
40 consent was obtained from participating adults or a parent/guardian for children aged <18 years. In
41 addition to parent/guardian consent, assent was also obtained from children aged 7-17 years.

42 The Bushbuckridge Municipality within the Ehlanzeni District is considered as predominantly rural,
43 with main industries being agriculture and tourism.² The Ehlanzeni District has a population of
44 1,828,738, with sixty percent of the district's population being >18 years of age (Appendix Table 1).
45 The City of Matlosana Municipality is considered to be 88.2% urban, and is located in the Dr Kenneth
46 Kaunda District, which has a population of 797,715.³ Sixty-five percent of the district population is
47 aged >18 years (Appendix Table 1). At both sites, the percentage of children, females, and
48 unemployed individuals were higher in the cohort than in the district (Appendix Table 1).

49 *Data sources*

- 50 • Population denominators⁴

51 Population numbers for each district, by age, were obtained from the StatsSA 2020 mid-year
52 population estimates for 2020.

- 53 • Notifiable Medical Conditions Surveillance System (NMCSS)⁵

54 Reverse transcription polymerase chain reaction (RT-PCR) testing in South Africa to detect SARS-
55 CoV-2 RNA started on 28 January 2020. Rapid SARS-CoV-2 antigen testing was implemented in
56 November 2020. All laboratories in the private and public sector performing SARS-CoV-2 tests
57 automatically feed testing data from their lab information systems to the NMCSS, from where
58 daily and weekly reporting on national, provincial and district SARS-CoV-2 infections are
59 performed. No serology tests are used for this reporting. Results from antigen tests may be
60 underestimated in the NMCSS. The number of cases reported to the NMCSS in the Ehlanzeni
61 District (rural community) and Dr Kenneth Kaunda District (urban community) was used as an

62 estimate of reported, laboratory-confirmed SARS-CoV-2 infections. Wave 1: 3 March – 21
63 November 2020, wave 2: 22 November 2020 – 27 March 2021.

64 • COVID-19 National Hospital Surveillance (DATCOV) ⁶

65 DATCOV is a national hospital surveillance system to which all hospitals where COVID-19
66 admissions occurred in the public and private sector in South Africa report to. The case
67 definition includes any person admitted with a positive RT-PCR test for SARS-CoV-2. In-hospital
68 outcome was available for all patients. The total number of hospitalisations and in-hospital
69 deaths in each district reported to DATCOV between 3 March – 21 November 2020 (wave 1) and
70 22 November 2020 – 27 March 2021 (wave 2) was used to calculate in the IHR and minimum IFR,
71 respectively.

72 • South African Medical Research Council (SAMRC) report on weekly deaths ⁷

73 The Burden of Disease Unit at the SAMRC produces a weekly report on excess deaths in South
74 Africa. Deaths in South Africa are registered on the Department of Home Affairs's National
75 Population Register and includes all citizens with a South African identification number. The
76 number of excess deaths were defined as the number of all-cause deaths in that week minus the
77 number of deaths expected for the week based on 2014-2019 trends. Excess death estimates are
78 adjusted for incomplete reporting, and death estimates in provinces are age-standardised to the
79 national population. Eighty-five percent of the reported excess deaths were used to calculate
80 the maximum IHR. In both provinces, excess deaths were only available starting 21 June (urban)
81 and 28 June 2020 (rural), and not from March as for infections and hospitalisations, therefore
82 the period for wave 1 in the rural community was defined as 28 June – 21 November 2020, and
83 as 21 June – 21 November 2020 in urban communities for wave 1. For both communities wave 2
84 was defined as 22 November 2020 – 26 March 2021. The wave-specific excess death rates were
85 kindly provided by Prof. Rob Dorrington.

86

87 **Appendix tables**

88 **Appendix Table 1.** Comparison of characteristics between district (Ehlanzeni and Dr Kenneth Kaunda
 89 Districts)⁴ and PHIRST-C cohort population, 2020, South Africa.

	Ehlanzeni District	Rural community cohort	p-value	Dr Kenneth Kaunda Districts	Urban community cohort	p-value
Age group (years)						
<5	203727/1828739 (11%)	99/668 (15%)	<0.01	75574/797716 (9%)	56/598 (9%)	0.93
5-12	319208/1828739 (17%)	210/668 (31%)	<0.01	121145/797716 (15%)	132/598 (22%)	<0.01
13-18	207344/1828739 (11%)	89/668 (13%)	0.11	82582/797716 (10%)	82/598 (14%)	0.01
19-34	491914/1828739 (27%)	108/668 (16%)	<0.01	212152/797716 (27%)	120/598 (20%)	<0.01
35-59	462982/1828739 (25%)	89/668 (13%)	<0.01	237146/797716 (30%)	122/598 (20%)	<0.01
≥60	143564/1828739 (8%)	46/668 (7%)	0.35	69117/797716 (9%)	58/598 (10%)	0.37
Female sex	961384/1828739 (53%)	427/668 (64%)	<0.01	405734/797716 (51%)	336/598 (56%)	0.01
Unemployed	187428/530865 (35%)	198/270 (73%)	<0.01	76654/257457 (30%)	202/315 (64%)	<0.01

90

91 **Appendix Table 2.** Number of sera collected (n) from consenting PHIRST-C participants (N) and
 92 percentage sampled during blood draws (BD) in the rural and urban community by blood draw, site,
 93 age group, March 2020 – March 2021, South Africa.
 94 Baseline (BD1) 20 July – 17 September 2020, second draw (BD2) 21 September – 10 October 2020,
 95 third draw (BD3) 23 November – 12 December 2020, fourth draw (BD4) 25 January – 20 February
 96 2021, fifth draw (BD5) 22 March – 11 April 2021.

	Rural n/N (%)						
	B1	B2	B3	B4	B5	B1-5	B3,5
<5 years	25/102 (25)	49/102 (48)	78/102 (76)	87/102 (85)	89/102 (87)	17/102 (17)	76/102 (75)
5-12 years	148/215 (69)	169/215 (79)	195/215 (91)	202/215 (94)	201/215 (93)	136/215 (63)	193/215 (90)
13-18 years	69/94 (73)	72/94 (77)	80/94 (85)	82/94 (87)	78/94 (83)	61/94 (65)	76/94 (81)
19-34 years	87/117 (74)	88/117 (75)	91/117 (78)	91/117 (78)	95/117 (81)	62/117 (53)	89/117 (76)
35-59 years	76/91 (84)	77/91 (85)	80/91 (88)	81/91 (89)	82/91 (90)	66/91 (73)	78/91 (86)
≥60 years	40/49 (82)	39/49 (80)	44/49 (90)	45/49 (92)	42/49 (86)	35/49 (71)	41/49 (84)
All ages	445/668 (67)	494/668 (74)	568/668 (85)	588/668 (88)	587/668 (88)	377/668 (56)	553/668 (83)
	Urban n/N (%)						
	B1	B2	B3	B4	B5	B1-5	B3,5
<5 years	45/57 (79)	50/57 (88)	50/57 (88)	44/57 (77)	48/57 (84)	33/57 (58)	45/57 (79)
5-12 years	116/135 (86)	116/135 (86)	125/135 (93)	123/135 (91)	122/135 (90)	103/135 (76)	120/135 (89)
13-18 years	75/84 (89)	75/84 (89)	81/84 (96)	77/84 (92)	78/84 (93)	69/84 (82)	78/84 (93)
19-34 years	102/130 (78)	98/130 (75)	100/130 (77)	99/130 (76)	98/130 (75)	77/130 (59)	92/130 (71)
35-59 years	110/130 (85)	110/130 (85)	117/130 (90)	112/130 (86)	111/130 (85)	98/130 (75)	111/130 (85)
≥60 years	57/62 (92)	55/62 (89)	56/62 (90)	55/62 (89)	53/62 (85)	51/62 (82)	53/62 (85)
All ages	505/598 (84)	504/598 (84)	529/598 (88)	510/598 (85)	510/598 (85)	431/598 (72)	499/598 (83)

97

98 **Appendix Table 3.** Individuals seropositive for SARS-CoV-2 antibodies with adjusted seroprevalence
 99 and 95% creditable intervals by blood draw, site and age, July 2020 – April 2021, South Africa.
 100 Baseline (BD1) 20 July – 17 September 2020, second draw (BD2) 21 September – 10 October 2020,
 101 third draw (BD3) 23 November – 12 December 2020, fourth draw (BD4) 25 January – 20 February
 102 2021, fifth draw (BD5) 22 March – 11 April 2021.

	BD1	BD2	BD3	BD4	BD5
<5 years	0/25 (4, 0-13)	1/49 (4, 0-13)	2/78 (4, 1-9)	14/87 (17, 10-25)	15/89 (18, 10-26)
5-12 years	2/148 (2, 0-5)	5/169 (3, 0-5)	7/195 (4, 2-7)	29/202 (15, 10-20)	39/201 (20, 14-25)
13-18 years	1/69 (3, 0-7)	5/72 (8, 0-7)	8/80 (11, 5-18)	20/82 (25, 16-35)	24/78 (31, 22-42)
Rural 19-34 years	0/87 (1, 0-4)	5/88 (7, 0-4)	13/91 (15, 8-23)	33/91 (37, 27-47)	35/95 (37, 28-47)
35-59 years	1/76 (2, 0-7)	5/77 (7, 0-7)	7/80 (10, 4-17)	23/81 (29, 20-39)	27/82 (33, 23-44)
≥60 years	1/40 (5, 0-13)	4/39 (12, 0-13)	4/44 (11, 3-21)	8/45 (19, 9-32)	10/42 (25, 13-38)
All ages	5/445 (1, 0-2)	25/494 (5, 0-2)	41/568 (7, 5-9)	127/588 (22, 18-25)	150/587 (26, 22-29)
<5 years	2/45 (6, 1-15)	5/50 (11, 4-21)	7/50 (15, 7-26)	8/44 (20, 9-32)	13/48 (28, 17-41)
5-12 years	11/116 (10, 5-16)	17/116 (15, 9-22)	24/125 (20, 13-27)	32/123 (26, 19-34)	38/122 (31, 23-40)
13-18 years	14/75 (19, 11-29)	19/75 (26, 17-36)	30/81 (37, 27-48)	35/77 (46, 35-56)	41/78 (53, 42-64)
Urban 19-34 years	10/102 (10, 5-17)	17/98 (18, 11-26)	23/100 (23, 16-32)	29/99 (30, 21-39)	34/98 (35, 26-44)
35-59 years	33/110 (30, 22-39)	45/110 (41, 32-50)	52/117 (45, 36-54)	61/112 (55, 45-64)	65/111 (59, 49-68)
≥60 years	3/57 (7, 2-14)	6/55 (12, 5-22)	7/56 (14, 6-24)	16/55 (30, 19-42)	18/53 (35, 22-47)
All ages	73/505 (15, 12-18)	109/ (22, 18-25)	143/529 (27, 23-31)	181/510 (36, 32-40)	209/510 (41, 37-45)

103

104 **Appendix Table 4.** SARS-CoV-2 seroprevalence from the fifth blood collection (22 March – 11 April
 105 2021), by site, age group and HIV status, South Africa.

	Rural			Urban		
	HIV-uninfected	HIV-infected	p-value	HIV-uninfected	HIV-infected	p-value
<5 years	15/87 (17)	0/1 (0)	0.65	12/46 (26)	0/1 (0)	0.55
5-12 years	37/195 (19)	0/2 (0)	0.49	35/116 (30)	1/3 (33)	0.91
13-18 years	21/66 (32)	0/3 (0)	0.24	38/73 (52)	3/4 (75)	0.37
19-34 years	22/65 (34)	10/23 (43)	0.41	26/73 (36)	7/19 (37)	0.92
35-59 years	12/36 (33)	12/39 (31)	0.81	37/61 (61)	28/47 (60)	0.91
≥60 years	6/27 (22)	4/10 (40)	0.28	17/46 (37)	1/7 (14)	0.24
All ages	113/476 (24)	26/78 (33)	0.07	165/415 (40)	40/81 (49)	0.11

106

107


108

109

110

111 **Appendix figures**

112




113

114 **Appendix Figure 1.** Location of study sites PHIRST-C, South Africa.

115 The rural site is located in Agincourt, Ehlanzeni District (dark green), Mpumalanga Province (light

116 green) and the urban site in Jouberton, Dr Kenneth Kaunda District (dark orange), North West

117 Province (light orange).



118

119 **Appendix Figure 2.** WHO population age-standardised SARS-CoV-2 infection, diagnosis,
 120 hospitalisation and deaths per 100,000 population in a rural community during a) wave 1 and b)
 121 wave 2, and urban community during c) wave 1 and d) wave 2 of infections, South Africa, March
 122 2020 - March 2021.

123 ¹ Based on seroprevalence at third/fifth blood draw. ² Laboratory confirmed SARS-CoV-2 cases
 124 reported from districts from national SARS-CoV-2 surveillance (NMCSS, wave 1: 3 March – 21
 125 November 2020, wave 2: 22 November 2020 – 27 March 2021). ³ Hospitalisations in the district
 126 based on COVID-19 Sentinel Hospital Surveillance (DATCOV, wave 1: 5 March – 21 November 2020,
 127 wave 2: 22 November 2020 – 27 March 2021). ⁴ Minimum estimate: in-hospitalisation deaths in
 128 districts based on COVID-19 Sentinel Hospital Surveillance report (DATCOV, wave 1: 5 March – 21
 129 November 2020, wave 2: 22 November 2020 – 27 March 2021), maximum estimate: provincial
 130 excess deaths reported by South African Medical Research Council (rural wave 1: 28 June – 21
 131 November 2020, urban wave 1: 21 June – 21 November 2020, wave 2: 22 November 2021 – 26
 132 March 2021). Wave 1: 1 March – 21 November 2020), wave 2 22 November 2020 – 27 March 2021.
 133 Values in bracket refer to 95% credible interval for infections and 95% confidence interval for all
 134 other estimates

Name	Affiliation
Amelia Buys	Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Anne von Gottberg	Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Cheryl Cohen	Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
F. Xavier Gómez-Olivé	MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Floidy Wafawanaka	MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Jackie Kleynhans	Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Jacques du Toit	MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Jinal N. Bhiman	Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Jocelyn Moyes	Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Kathleen Kahn	MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Kgaugelo Patricia Kgasago	Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Limakatso Lebina	Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Linda de Gouveia	Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Maimuna Carrim	Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Meredith L. McMorrow Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.

Mignon du Plessis Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Neil A. Martinson Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa. Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of America.

Nicole Wolter Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Retshidisitwe Kotane Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Stefano Tempia Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. MassGenics, Atlanta, Georgia, United States of America.

Stephen Tollman MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Science, University of the Witwatersrand.

Tumelo Moloantoa Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150 **References**

- 151 1. Cohen C, Kleynhans J, Moyes J, et al. Asymptomatic transmission and high community
152 burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18
153 (PHIRST): a population cohort study. *The Lancet Global Health* 2021; **9**(6): e863-e74.
- 154 2. Bushbuckridge local municipality. Bushbuckridge local municipality final integrated
155 development plan 2020/21. 2020. [https://www.cogta.gov.za/cgta_2016/wp-](https://www.cogta.gov.za/cgta_2016/wp-content/uploads/2021/02/Bushbuckridge-Municipality.pdf)
156 [content/uploads/2021/02/Bushbuckridge-Municipality.pdf](https://www.cogta.gov.za/cgta_2016/wp-content/uploads/2021/02/Bushbuckridge-Municipality.pdf) (accessed 16 February 2021 16 February
157 2021).
- 158 3. City of Marlosana. Matlosana Spatial Development Framework. 2009.
159 <http://www.matlosana.gov.za/Documents/Policies/SPLUMA/SDF%20FRAMEWORK%202009.pdf>
160 (accessed 16 February 2021 16 February 2021).
- 161 4. Statistics South Africa. Statistical release P0302 - Mid-year population estimates 2020. 2020.
162 http://www.statssa.gov.za/?page_id=1854&PPN=P0302&SCH=7263414 May 2021).
- 163 5. National Institute for Communicable Diseases. COVID-19 Weekly Epidemiology Brief Week
164 19. 22 May 2021 2021. [https://www.nicd.ac.za/wp-content/uploads/2021/05/COVID-19-Weekly-](https://www.nicd.ac.za/wp-content/uploads/2021/05/COVID-19-Weekly-Epidemiology-Brief-week-19-2021.pdf22)
165 [Epidemiology-Brief-week-19-2021.pdf22](https://www.nicd.ac.za/wp-content/uploads/2021/05/COVID-19-Weekly-Epidemiology-Brief-week-19-2021.pdf22) May 2021).
- 166 6. National Institute for Communicable Diseases. COVID-19 Sentinel Hospital Surveillance
167 Update Week 18. 14 May 2021 2021. [https://www.nicd.ac.za/wp-content/uploads/2021/05/NICD-](https://www.nicd.ac.za/wp-content/uploads/2021/05/NICD-COVID-19-Weekly-Sentinel-Hospital-Surveillnace-update-Week-18-2021.pdf22)
168 [COVID-19-Weekly-Sentinel-Hospital-Surveillnace-update-Week-18-2021.pdf22](https://www.nicd.ac.za/wp-content/uploads/2021/05/NICD-COVID-19-Weekly-Sentinel-Hospital-Surveillnace-update-Week-18-2021.pdf22) May 2021).
- 169 7. South African Medical Research Council. Report on Weekly Deaths in South Africa Week 18.
170 10 May 2021 2021. <https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa> (accessed
171 22 May 20021).

172